

POSTER PRESENTATION

Open Access

# Eletriptan provides consistent migraine relief: results of a within-patient multiple-dose study

M Almas<sup>1</sup>, S Tepper<sup>2</sup>, S Landy<sup>3</sup>, E Ramos<sup>1\*</sup>

From The European Headache and Migraine Trust International Congress  
London, UK. 20-23 September 2012

## Objective

To evaluate the consistency of response to eletriptan in migraine.

## Background

Surveys indicate that more than 40% of individuals have an average headache frequency of 2 or more attacks per month. Lack of consistent response has been cited in patient surveys as one of the top 3 reasons for dissatisfaction with migraine treatments.

## Methods

Patients first completed an open-label, lead-in period in which they treated 3 migraine attacks with eletriptan 40 mg. Based on response to open-label treatment, patients were treated with either eletriptan 40 mg (E40; N=539) or eletriptan 80 mg (E80; N=432) in a 4-attack consistency of response study in which placebo was substituted, in a randomized, double-blind fashion, for the treatment of one attack. Headache response was defined as improvement at 2 hours post-dose to a headache intensity of none (pain-free) or mild. Within-patient consistency was defined a priori as headache response at 2 hours on at least 2 out of 3 attacks.

## Results

During double-blind treatment, within-patient consistency was 77% for E40 and 73% for E80. For patients (N=47) who had responded to 0/3 attacks on E40 in the open-label phase, titration to the E80 dose resulted in headache response in 55%. A repeated measures logistic regression analysis found that sustained headache response at 24 hours, averaged across 3 attacks, was significantly higher on both E40 vs. placebo (49% vs. 32%;  $p < 0.001$ ) and E80 vs. placebo (43% vs. 11%;  $p < 0.001$ ). Sustained pain-free at 24 hours, averaged across all 3

attacks, was also significantly higher on both E40 vs. placebo (30% vs. 5%;  $p < 0.001$ ) and E80 vs. placebo (25% vs. 3%;  $p < 0.001$ ).

## Conclusion

Eletriptan showed consistent and sustained efficacy in the treatment of migraine. Funded by Pfizer Inc.

## Author details

<sup>1</sup>Pfizer Inc, USA. <sup>2</sup>Cleveland Clinic, USA. <sup>3</sup>Wesley Neurology and Headache Clinic, USA.

Published: 21 February 2013

doi:10.1186/1129-2377-14-S1-P131

**Cite this article as:** Almas et al.: Eletriptan provides consistent migraine relief: results of a within-patient multiple-dose study. *The Journal of Headache and Pain* 2013 **14**(Suppl 1):P131.

## Submit your manuscript to a SpringerOpen<sup>®</sup> journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](http://springeropen.com)

<sup>1</sup>Pfizer Inc, USA

Full list of author information is available at the end of the article